Compare Citius Pharmaceuticals Inc (CTXR) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Paycom Software Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Paycom Software Inc trades at $144.18 (market cap $6.70B). The key difference: Paycom Software Inc is far larger — about 457.7× Citius Pharmaceuticals Inc's market cap, and Paycom Software Inc pays a 1.04% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | PAYC | |
|---|---|---|
Market Cap | $14.64M | $6.70B |
Sector | Health | Technology |
52-Week High | $1.82 | $238.80 |
52-Week Low | $0.53 | $113.59 |
Enterprise Value | $10.86M | $7.31B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Paycom Software (PAYC) trades at $146.50, up 5.34% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 22.44% net income margin and 37.15% ROE, though Q2 2026 earnings are pending. Recent news highlights product innovation with the launch of Asset Management tool and board appointments, supporting growth prospects in the HCM software sector.
Outlook remains positive with analyst consensus price target of $151 suggesting modest upside, balanced by high valuation multiples and competitive pressures. Key risks include execution challenges in maintaining growth momentum and sensitivity to economic cycles affecting HR software demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
